Cargando…
Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare form of liver cancer with a poor prognosis. The therapeutic options for patients with advanced ICC are limited and usually ineffective. There is currently no approved targeted therapy for ICC, although accumulating evidence supports inhibiti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483506/ https://www.ncbi.nlm.nih.gov/pubmed/28694672 http://dx.doi.org/10.3748/wjg.v23.i23.4311 |
_version_ | 1783245774496202752 |
---|---|
author | Bian, Ji-Lai Wang, Mei-Mei Tong, En-Juan Sun, Jing Li, Ming Miao, Zhi-Bo Li, Yan-Lin Zhu, Bai-Hong Xu, Jia-Jia |
author_facet | Bian, Ji-Lai Wang, Mei-Mei Tong, En-Juan Sun, Jing Li, Ming Miao, Zhi-Bo Li, Yan-Lin Zhu, Bai-Hong Xu, Jia-Jia |
author_sort | Bian, Ji-Lai |
collection | PubMed |
description | Intrahepatic cholangiocarcinoma (ICC) is a relatively rare form of liver cancer with a poor prognosis. The therapeutic options for patients with advanced ICC are limited and usually ineffective. There is currently no approved targeted therapy for ICC, although accumulating evidence supports inhibition of the PI3K/Akt/mTOR signaling pathway as a promising therapeutic strategy in the treatment of ICC. Here, we report a patient with stage IV ICC harboring a PIK3CA mutation who responded well to the mTOR inhibitor everolimus. Computed tomography and magnetic resonance imaging demonstrated shrinkage of the tumor and maintenance of a partial response for 6.5 mo after everolimus treatment as the best response. To the best of our knowledge, this is the first clinical case report in the literature of clinical benefit from everolimus treatment in an ICC patient with PIK3CA mutation. |
format | Online Article Text |
id | pubmed-5483506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-54835062017-07-10 Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation Bian, Ji-Lai Wang, Mei-Mei Tong, En-Juan Sun, Jing Li, Ming Miao, Zhi-Bo Li, Yan-Lin Zhu, Bai-Hong Xu, Jia-Jia World J Gastroenterol Case Report Intrahepatic cholangiocarcinoma (ICC) is a relatively rare form of liver cancer with a poor prognosis. The therapeutic options for patients with advanced ICC are limited and usually ineffective. There is currently no approved targeted therapy for ICC, although accumulating evidence supports inhibition of the PI3K/Akt/mTOR signaling pathway as a promising therapeutic strategy in the treatment of ICC. Here, we report a patient with stage IV ICC harboring a PIK3CA mutation who responded well to the mTOR inhibitor everolimus. Computed tomography and magnetic resonance imaging demonstrated shrinkage of the tumor and maintenance of a partial response for 6.5 mo after everolimus treatment as the best response. To the best of our knowledge, this is the first clinical case report in the literature of clinical benefit from everolimus treatment in an ICC patient with PIK3CA mutation. Baishideng Publishing Group Inc 2017-06-21 2017-06-21 /pmc/articles/PMC5483506/ /pubmed/28694672 http://dx.doi.org/10.3748/wjg.v23.i23.4311 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Bian, Ji-Lai Wang, Mei-Mei Tong, En-Juan Sun, Jing Li, Ming Miao, Zhi-Bo Li, Yan-Lin Zhu, Bai-Hong Xu, Jia-Jia Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title_full | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title_fullStr | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title_full_unstemmed | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title_short | Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a PIK3CA mutation |
title_sort | benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a pik3ca mutation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483506/ https://www.ncbi.nlm.nih.gov/pubmed/28694672 http://dx.doi.org/10.3748/wjg.v23.i23.4311 |
work_keys_str_mv | AT bianjilai benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT wangmeimei benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT tongenjuan benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT sunjing benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT liming benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT miaozhibo benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT liyanlin benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT zhubaihong benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation AT xujiajia benefitofeverolimusintreatmentofanintrahepaticcholangiocarcinomapatientwithapik3camutation |